OT A201
Alternative Names: OT-A201Latest Information Update: 25 Jan 2024
At a glance
- Originator Biomunex Pharmaceuticals
- Developer Biomunex Pharmaceuticals; Onward Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
- Preclinical Cancer
Most Recent Events
- 24 Jan 2024 Onward Therapeutics initiates enrolment in a phase-I clinical trial in Haematological malignancies (Second-line therapy or greater, Monotherapy) in France (IV)
- 27 Jun 2023 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater, Combination therapy) in France (IV) (NCT05828459)
- 27 Jun 2023 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater, Monotherapy) in France (IV) (NCT05828459)